Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV5-hFIX dose-ascending phase I/II study in adults with severe or moderately severe haemophilia B
NL-OMON46967Phase 2Active, not recruiting
- Sponsor
- uniQure
- Start
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of AAV5-hFIX in hemophilia B (HB) (2 cohorts), sponsored by uniQure. Primary endpoint: Adverse events. Started Aug 2015; status: active, not recruiting.
02
Drugs
AAV5-hFIX
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON46967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46967.